Mass Tort Lead Generation — Priced on Signed Retainers, Not Cost Per Lead

Why mass tort lead generation costs more than standard PI

Mass tort lead generation carries a higher cost per signed retainer than most other legal marketing because four forces compound at once. The first is case value. A qualifying claimant in an active MDL can represent a settlement position worth far more than a single-plaintiff soft-tissue auto case, so firms compete hard for each one and bid acquisition budgets up accordingly. Cost tracks value: the leads that anchor a viable tort inventory are priced against the cases they can become.

The second force is the ad auction itself. Every firm and lead vendor chasing the same tort bids on the same finite pool of high-intent keywords, placements, and audiences. When a new MDL consolidates or a bellwether trial date lands, demand spikes on the exact terms injured claimants search, and click prices rise across Google, YouTube, and Meta at the same time. Mass tort lead generation runs inside these auctions, so media cost moves with litigation news, not with a fixed rate card.

The third force is qualification difficulty. A raw lead is not a qualified claimant. Tort-specific eligibility — an exposure window, a documented diagnosis, a prescribing date, a state of residence — disqualifies a large share of the inquiries a campaign generates. We screen every claimant against six checkpoints, and that intake labor is spent whether or not a claimant passes; the cost of the ones who wash out is absorbed into the price of the ones who convert to a live transfer. Narrower criteria mean more spend per surviving claimant.

The fourth force is time. The path from raw lead to signed retainer is rarely same-day. Claimants request records, weigh whether to join the litigation, and complete retainer paperwork over days or weeks, and a share never sign at all. Media spends up front while retainers close later, so the working capital behind each signed case sits at risk for the length of that cycle. Priced honestly, mass tort lead generation has to carry that gap — which is why we bill on cost per signed retainer rather than cost per lead, and reconcile the two every week.

For the retaining firm, these four forces are exactly why the pricing model matters. On a cost-per-lead arrangement, the firm absorbs all four — paying for volume regardless of how many raw leads survive screening or how long retainers take to close. Pricing on cost per signed retainer moves that exposure onto us: our margin earns only when a qualified claimant becomes a signed retainer, so the incentive to control auction spend, screening yield, and cycle time sits with the party running the campaigns.

Why cost per signed retainer varies by tort

The ranges in the table above are not arbitrary. Cost per signed retainer moves from tort to tort because three variables set the price of a qualified claimant, and they rarely move together.

Criteria complexity comes first. A tort with a wide, easily documented qualifying profile converts a larger share of raw leads into qualified claimants, so the acquisition cost spreads across more signed retainers. A tort that demands a specific diagnosis, a narrow exposure window, and contemporaneous records disqualifies most inquiries, and the spend on everyone who washes out loads onto the few who sign. Camp Lejeune, with its defined 1953–1987 stationing window, screens differently than a pharmaceutical tort that requires prescription history plus a confirmed adverse-event diagnosis — and the CPSR reflects that gap.

Competition comes second. The number of firms and vendors bidding on a tort sets the auction price of its keywords, placements, and audiences. A heavily advertised tort with national television and saturated search — Roundup, Camp Lejeune — carries higher media costs than an emerging tort few competitors have discovered yet. When a tort is early and under-marketed, acquisition can be comparatively cheap; at peak competition, the same qualified claimant costs materially more.

MDL stage comes third. Cost per signed retainer shifts across the life of a litigation. Early, before consolidation and before filing deadlines drive urgency, claimant awareness is low and volume is hard to build. At peak — around bellwether trials, settlement news, or an approaching statute deadline — search demand and competition both spike, raising media costs even as claimant intent runs highest. Late, as a tort winds down and criteria tighten, qualifying claimants grow scarce. We calibrate each firm’s CPSR target to where its tort sits on that curve, then rebalance channel mix as the stage changes.

The table above reflects all three variables at once. A tort like Suboxone or Depo-Provera, at the lower end of the CPSR range, tends to combine a more workable qualifying profile with lighter competition. Camp Lejeune sits toward the higher end because a documented service window, a crowded advertising field, and mature-stage urgency stack on top of one another. Two torts with comparable case value can still carry very different costs per signed retainer once criteria, competition, and stage are accounted for.

This is why the table gives ranges rather than a single figure, and why we quote a firm-specific number only after mapping your case criteria against the tort’s current competition and MDL stage.